The Journal of Immunology, Vol 155, Issue 5 2427-2436, Copyright © 1995 by American Association of Immunologists

ARTICLES

Deoxyspergualin inhibits kappa light chain expression in 70Z/3 pre-B cells by blocking lipopolysaccharide-induced NF-kappa B activation

MA Tepper, SG Nadler, JM Esselstyn and KG Sterbenz
Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, WA 98121, USA.

Deoxyspergualin (DSG) is a potent immunosuppressive agent that is currently undergoing clinical trials for treatment of transplant rejection, preventive of human anti-mouse Ab response, and blocking autoimmune disease progression. The mechanism of action of DSG appears to be novel, with in vivo activity attributable to the suppression of both humoral and cell-mediated immunity. In this study we investigated the effect of DSG on the induction of lg expression in the 70Z/3 murine pre-B cell line. Treatment of 70Z/3 cells with DSG for 24, 48, or 72 h before LPS or IFN-gamma induction resulted in a time-dependent inhibition of surface lgM expression, with greater than 80% inhibition observed after 72 h of pretreatment. Inhibition of surface expression was specific for lgM, as neither MHC class I nor CD45 (B220) surface expression was affected by DSG pretreatment. Cyclosporin A was ineffective at suppressing surface igM induction. DSG pretreatment results in a 10-fold reduction in LPS- or IFN-gamma-induced kappa L chain protein and mRNA expression. No change was observed in either mu or beta-actin mRNA levels. Analysis of nuclear and cytoplasmic NF-kappa B expression using electrophoretic mobility shift analysis and Western analysis, revealed that DSG blocked LPS-induced NF-kappa B nuclear translocation, but had no effect on cytoplasmic NF-kappa B levels. We conclude that DSG may act to suppress humoral immune responses by blocking the transcriptional activation of kappa L chain expression during certain stages of B cell development.

This article has been cited by other articles:

				R. Birck, M. Newman, C. Braun, I. Neumann, K. Nemoto, B. Yard, R. Waldherr, and F. J. van der Woude 15-Deoxyspergualin and cyclophosphamide, but not mycophenolate mofetil, prolong survival and attenuate renal disease in a murine model of ANCA-associated crescentic nephritis Nephrol. Dial. Transplant., January 1, 2006; 21(1): 58 - 63. [Abstract] [Full Text] [PDF]

				W. H. Schmitt, R. Birck, P. A. Heinzel, U. Gobel, M. Choi, K. Warnatz, H. H. Peter, and F. J. van der Woude Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients Nephrol. Dial. Transplant., June 1, 2005; 20(6): 1083 - 1092. [Abstract] [Full Text] [PDF]

				P. E. Rao, A. L. Petrone, and P. D. Ponath Differentiation and Expansion of T Cells with Regulatory Function from Human Peripheral Lymphocytes by Stimulation in the Presence of TGF-{beta} J. Immunol., February 1, 2005; 174(3): 1446 - 1455. [Abstract] [Full Text] [PDF]

				J. Yang, S. M. Bernier, T. E. Ichim, M. Li, X. Xia, D. Zhou, X. Huang, G. H. Strejan, D. J. White, R. Zhong, et al. LF15-0195 generates tolerogenic dendritic cells by suppression of NF-{kappa}B signaling through inhibition of IKK activity J. Leukoc. Biol., September 1, 2003; 74(3): 438 - 447. [Abstract] [Full Text] [PDF]

				R. Birck, K. Warnatz, H. M. Lorenz, M. Choi, M. Haubitz, M. Grunke, H. H. Peter, J. R. Kalden, U. Gobel, J. M. Drexler, et al. 15-Deoxyspergualin in Patients with Refractory ANCA-Associated Systemic Vasculitis: A Six-Month Open-Label Trial to Evaluate Safety and Efficacy J. Am. Soc. Nephrol., February 1, 2003; 14(2): 440 - 447. [Abstract] [Full Text] [PDF]

				H. Holcombe, I. Mellman, C. A. Janeway Jr., K. Bottomly, and B. N. Dittel The Immunosuppressive Agent 15-Deoxyspergualin Functions by Inhibiting Cell Cycle Progression and Cytokine Production Following Naive T Cell Activation J. Immunol., November 1, 2002; 169(9): 4982 - 4989. [Abstract] [Full Text] [PDF]

				S. M. Fujihara, J. S. Cleaveland, L. S. Grosmaire, K. K. Berry, K. A. Kennedy, J. J. Blake, J. Loy, B. M. Rankin, J. A. Ledbetter, and S. G. Nadler A D-Amino Acid Peptide Inhibitor of NF-{kappa}B Nuclear Localization Is Efficacious in Models of Inflammatory Disease J. Immunol., July 15, 2000; 165(2): 1004 - 1012. [Abstract] [Full Text] [PDF]

				D. F. Smith, L. Whitesell, and E. Katsanis Molecular Chaperones: Biology and Prospects for Pharmacological Intervention Pharmacol. Rev., December 1, 1998; 50(4): 493 - 514. [Abstract] [Full Text] [PDF]

				J.-I. Lee and G. J. Burckart Nuclear Factor Kappa B: Important Transcription Factor and Therapeutic Target J. Clin. Pharmacol., November 1, 1998; 38(11): 981 - 993. [Abstract] [PDF]

				C. Jiang, S. L. Fang, Y.-F. Xiao, S. P. O'Connor, S. G. Nadler, D. W. Lee, D. M. Jefferson, J. M. Kaplan, A. E. Smith, and S. H. Cheng Partial restoration of cAMP-stimulated CFTR chloride channel activity in Delta F508 cells by deoxyspergualin Am J Physiol Cell Physiol, July 1, 1998; 275(1): C171 - C178. [Abstract] [Full Text] [PDF]

				P. A. Kiener, M. N. Lioubin, L. R. Rohrschneider, J. A. Ledbetter, S. G. Nadler, and M. L. Diegel Co-ligation of the Antigen and Fc Receptors Gives Rise to the Selective Modulation of Intracellular Signaling in B Cells. REGULATION OF THE ASSOCIATION OF PHOSPHATIDYLINOSITOL 3-KINASE AND INOSITOL 5prime -PHOSPHATASE WITH THE ANTIGEN RECEPTOR COMPLEX J. Biol. Chem., February 7, 1997; 272(6): 3838 - 3844. [Abstract] [Full Text] [PDF]

				T. J. Brown, W. W. Shuford, W.-C. Wang, S. G. Nadler, T. S. Bailey, H. Marquardt, and R. S. Mittler Characterization of a CD43/Leukosialin-mediated Pathway for Inducing Apoptosis in Human T-Lymphoblastoid Cells J. Biol. Chem., November 1, 1996; 271(44): 27686 - 27695. [Abstract] [Full Text] [PDF]